RedHill Biopharma and RESprotect GmbH Sign a Binding Agreement for the Cancer Drug RP101
RedHill Biopharma, a biotechnology company based in Israel, had entered into a binding agreement with biotechnology company RESprotect GmbH for the exclusive rights to a cancer drug candidate for chemotherapy, as well as for other ‘next generation’ drugs.
The drug in question is RP101, a heat shock protein (Hsp27) inhibitor which is required to be taken orally. The drug can help prevent chemo-resistance, a condition where those undergoing chemotherapy become resistant to it and so their cancer cells, and consequently tumours, do not regress, rendering chemotherapy sessions ineffective. The drug works by allowing the tumour to remain sensitive to chemotherapy treatment and improving chances of survival.
The official agreement details that RedHill has the option, if it wishes, to acquire the rights to RP101 for all indications around the world (with the exception of a pancreatic cancer indication in South Korea.) RedHill is paying RESprotect for this option for one year, and it may be extended by RedHill depending on their strategy.
The drug has gone through phase II clinical trials and has received an orphan Drug designation from the FDA and EMA, specifically for the treatment of pancreatic cancer.
Read more about the agreement here: RedHill and RESprotect sign exclusive deal over cancer drug